Raymond James raised the firm’s price target on Insulet to $334 from $320 and keeps an Outperform rating on the shares. The company’s 11% revenue beat in Q4 points to "clear momentum" in the U.S. OP5 launch and the firm expects this dynamic to continue, said the analyst, who also noted that initial 2023 revenue guidance came in about 4% above the consensus forecast.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PODD:
- Insulet reports Q4 adjusted EPS 55c, consensus 21c
- DexCom selloff on Apple article should be bought, says Oppenheimer
- Insulet acquires assets of Automated Glucose Control for $25M
- Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
- Insulet initiated with a Peer Perform at Wolfe Research
